Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(4):482–494. doi: 10.1111/j.1750-3639.2003.tb00479.x

P‐Glycoprotein and Multidrug Resistance‐associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells

Oliver Bähr 1, Johannes Rieger 1, Frank Duffner 2, Richard Meyermann 3, Michael Weller 1, Wolfgang Wick 1,✉
PMCID: PMC8095903  PMID: 14655754

Abstract

Understanding and overcoming multidrug resistance (MDR) may be a promising strategy to develop more effective pharmacotherapies for malignant gliomas. In the present study, human malignant glioma cell lines (n = 12) exhibited heterogeneous mRNAand protein expression and functional activity of the mdr gene‐encoded P‐glycoprotein (PGP) and MDR‐associated protein (MRP). Correlation between mRNA expression, protein levels and functional activity was strong. Inhibition of PGP activity by verapamil or PSC 833 enhanced the cytotoxic effects of vincristine, doxorubicin, teniposide and taxol. Inhibition of MRP activity by indomethacin or probenecid enhanced the cytotoxic effects of vincristine, doxorubicin and teniposide. The human cerebral endothelial cell line, SV‐HCEC, exhibited the strongest PGP activity of all cell lines. Five primary human glioblastomas and one anaplastic astrocytoma displayed heterogenous protein levels of PGP and MRP‐1 in tumor cells and of PGP in biopsy specimens in vivo, but no functional activity of these proteins upon ex vivo culturing. These data suggest that the glioma cell line‐associated MDR‐type drug resistance is a result of long‐term culturing and that cerebral endothelial, but not glioma cells, may contribute to MDR‐type drug resistance of gliomas in vivo.

Full Text

The Full Text of this article is available as a PDF (592.6 KB).

References

  • 1. Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, Mori T, Hori S, Kohno K, Kuwano M (1994) Possible involvement of multidrug‐resistance‐associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int J Cancer 58:860–864. [DOI] [PubMed] [Google Scholar]
  • 2. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori S (1998) Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neuro-Oncol 40:11–18. [DOI] [PubMed] [Google Scholar]
  • 3. Ashmore SM, Thomas DG, Darling JL (1999) Does Pglycoprotein play a role in clinical resistance of malignant astrocytoma Anticancer Drugs 10:861–872. [DOI] [PubMed] [Google Scholar]
  • 4. Becker I, Becker KF, Meyermann R, Hollt V (1991) The multidrug‐resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol 82:516–519. [DOI] [PubMed] [Google Scholar]
  • 5. Borst P, Schinkel AH (1996) What have we learnt thus far from mice with disrupted P‐glycoprotein genes Eur J Cancer 32:985–990. [DOI] [PubMed] [Google Scholar]
  • 6. Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347–357. [DOI] [PubMed] [Google Scholar]
  • 7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug‐resistant human lung cancer cell line. Science 258:1650–1654. [DOI] [PubMed] [Google Scholar]
  • 8. Cordon‐Cardo C, O'Brien JP, Casals D, Rittman‐Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrugresistance gene (P‐glycoprotein) is expressed by endothelial cells at blood‐brain barrier sites. Proc Natl Acad Sci U S A 86:695–698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. De Angelis LM, Burger PC, Green SB, Cairncross JG (1998) Malignant glioma: who benefits from adjuvant chemotherapy Ann Neurol 44:691–695. [DOI] [PubMed] [Google Scholar]
  • 10. Decleves X, Fajac A, Lehmann‐Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM (2002) Molecular and functional MDR1‐PGP and MRPS expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173–180. [DOI] [PubMed] [Google Scholar]
  • 11. Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MM, Flens MJ, Scheper RJ, Veerman AJ (1997) Optimal immunocytochemical and flow cytometric detection of P‐gp, MRP and LRP in childhood acute lymphoblastic leukemia Leukemia 11:1078–1085. [DOI] [PubMed] [Google Scholar]
  • 12. Den Boer ML, Pieters R, Kazemier KM, Janka‐Schaub GE, Henze G, Veerman AJ (1998) The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia. Leukemia 12:912–920. [DOI] [PubMed] [Google Scholar]
  • 13. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruß T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood‐brain barrier in vitro and in vivo. J Clin Invest 110:1309–1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597. [DOI] [PubMed] [Google Scholar]
  • 15. Gottesman MM, Pastan I, Ambudkar SV (1996) P‐glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610–617. [DOI] [PubMed] [Google Scholar]
  • 16. Henson JW, Cordon‐Cardo C, Posner JB (1992) P‐glycoprotein expression in brain tumors. J Neuro-Oncol 14:37–43. [DOI] [PubMed] [Google Scholar]
  • 17. Huai‐Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, Miller DW (1998) Expression of multidrug resistance‐associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 243:816–820. [DOI] [PubMed] [Google Scholar]
  • 18. Kiwit JCW, Hertel A, Matuschek AE (1994) Reversal of chemoresistance in malignant gliomas by calcium antagonists: correlation with the expression of multidrug‐resist‐ant p‐glycoprotein. J Neurosurg 81:587–594. [DOI] [PubMed] [Google Scholar]
  • 19. Matsumoto T, Tani E, Kaba K, Shindo H, Miyaji K (1991) Expression of P‐glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 74:460–466. [DOI] [PubMed] [Google Scholar]
  • 20. Muruganandam A, Herx LM, Monette R, Durkin JP, Stanimirovic DB (1997) Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood‐brain barrier. FASEB J 11:1187–1197. [DOI] [PubMed] [Google Scholar]
  • 21. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, Roux F (1998) Mrp1 multidrug resistance‐associated protein and P‐glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705–715. [DOI] [PubMed] [Google Scholar]
  • 22. Regina A, Demeule M, Berube A, Moumdjian R, Berthelet F, Beliveau R (2003) Differences in multidrug resistance phenotype and matrix metalloproteinase activity between endothelial cells from normal brain and glioma. J Neurochem 84:316–324. [DOI] [PubMed] [Google Scholar]
  • 23. Rieger L, Rieger J, Winter S, Streffer J, Esser P, Dichgans J, Meyermann R, Weller M (2000) Evidence for a constitutive, verapamil‐sensitive, non‐P‐glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Acta Neuropathol 99:555–562. [DOI] [PubMed] [Google Scholar]
  • 24. Roller A, Bähr O, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M (1999) Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX‐1 and MRP. Biochem Biophys Res Commun 259:600–605. [DOI] [PubMed] [Google Scholar]
  • 25. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus‐Maandag EC, te Riele HP (1994) Disruption of the mouse mdr1a P‐glycoprotein gene leads to a deficiency in the blood‐brain barrier and to increased sensitivity to drugs. Cell 77:491–502. [DOI] [PubMed] [Google Scholar]
  • 26. Schinkel AH, Wagenaar E, Mol CA, Mol CA, Borst P (1996) P‐glycoprotein in the blood‐brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Takamiya Y, Abe Y, Tanaka Y, Tsugu A, Kazuno M, Oshika Y, Maruo K, Ohnishi Y, Sato O, Yamazaki H, Kijima H, Ueyama Y, Tamaoki N, Nakamura M (1997) Murine P‐glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts. Br J Cancer 76:445–450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Tanaka Y, Abe T, Tsugu A, Takamiya Y, Akatsuka A, Tsuruo T, Yamazaki H, Ueyama Y, Sato O, Tamaoki N (1994) Ultrastructural localization of P‐glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch 425:133–138. [DOI] [PubMed] [Google Scholar]
  • 29. Tóth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM (1996) MDR1 P‐glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149:853–858. [PMC free article] [PubMed] [Google Scholar]
  • 30. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79:640–644. [DOI] [PubMed] [Google Scholar]
  • 31. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M (1999) PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L‐induced apoptosis. Oncogene 18:3936–3943. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES